Search

Your search keyword '"Cognitive Symptoms"' showing total 1,365 results

Search Constraints

Start Over You searched for: Descriptor "Cognitive Symptoms" Remove constraint Descriptor: "Cognitive Symptoms"
1,365 results on '"Cognitive Symptoms"'

Search Results

251. Clinical Utility of the Mig-SCog.

252. Patterns of self-reported depressive symptoms in relation to morningness-eveningness in inpatients with a depressive disorder.

253. The effects of conscious sedation with nitrous oxide/oxygen on cognitive functions.

254. The UCLA study of Predictors of Cognitive Functioning Following Moderate/Severe Pediatric Traumatic Brain Injury.

255. The impact of cognitive symptoms on migraine attack-related disability.

256. Cognitive endophenotypes, gene–environment interactions and experience-dependent plasticity in animal models of schizophrenia.

257. Italian psychiatrists’ perception on cognitive symptoms in major depressive disorder.

258. Predicting return to work after subarachnoid hemorrhage using the Montreal Cognitive Assessment (MoCA).

259. Executive dysfunction, obsessive–compulsive symptoms, and attention deficit and hyperactivity disorder in Systemic Lupus Erythematosus: Evidence for basal ganglia dysfunction?

260. Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders.

261. Endophenotypical drift in Huntington’s disease:a 5-year follow-up study

262. P108 Characteristics of long COVID: findings from a social media survey

263. Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders

264. Pharmaco-Magnetic Resonance as Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders

265. Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia

266. Editorial: Understanding Early Detection Markers in Schizophrenia

267. Editorial: Understanding Early Detection Markers in Schizophrenia

268. Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease

270. Escala de síntomas cognitivos en depresión (EsADFUN)

271. Contributing factors to quality of life after vertebral artery dissection: a prospective comparative study

272. Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

273. The Effect of Induced and Chronic Pain on Attention

274. Use of patient-generated health data across healthcare settings: implications for health systems

275. Assessing behavior and cognition in rodents, nonhuman primates, and humans: where are the limits of translation?

276. 288 Hearing Loss as a Potentially Modifiable Risk Factor in People with Mild Cognitive Symptoms Attending a Specialist Memory Service

277. 127 Modifiable Cardiovascular Risk Profile in People with Mild Cognitive Symptoms Attending a Memory Service - an Opportunity to Promote Brain Health

278. Dementia and associated factors among the elderly in Vietnam: a cross-sectional study

279. Immigration Transition and Cognitive Symptoms During Menopausal Transition

280. Stress in Relation to Anxiety and Depression Among Racial/Ethnic Minority Women: The Differential Impact of Cultural Mismatch on Somatic and Cognitive Symptoms

281. Fibromyalgia and dissociative symptoms

282. The myotonic dystrophy experience: a North American cross‐sectional study

283. Alzheimer's Disease Classification Based on Multi-feature Fusion

284. Thyroid-stimulating hormone in hypothyroidism – How high is too high?

285. Maternal immune activation in mid-late gestation alters amphetamine sensitivity and object recognition, but not other schizophrenia-related behaviours in adult rats

286. Guidelines for the treatment of patients with dementia

287. Progress in mechanistically novel treatments for schizophrenia

288. The psychotropic effect of vitamin D supplementation on schizophrenia symptoms

289. Validation of the Finnish version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and evaluation of the applicability of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and the Fatigue Scale for Motor and Cognitive Functions (FSMC)

290. BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review

291. Depression, Health Comorbidities, Cognitive Symptoms and Their Functional Impact: Not Just a Geriatric Problem

292. Increased sigma-1 receptor (S1R) availability and its association with depressive and cognitive symptoms in untreated patients with acute early onset unipolar depression (EO-UP): a (-)-F-18-Fluspidine PET study

293. Cognition and Mental Health in Pediatric Patients Following COVID-19.

294. Impaired Decision-Making Capacity in the Elderly King David (c. 1040-970 BCE): Was Hypothyroidism the Underlying Cause?

295. Relationship between subjective report and objective assessment of neurocognitive functioning in persons with multiple sclerosis.

296. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.

297. Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.

298. Abnormal resting-state functional connectivity underlies cognitive and clinical symptoms in patients with schizophrenia.

299. Brain Tumor at Diagnosis: From Cognition and Behavior to Quality of Life.

300. Telephone-Delivered Interventions for Suicide Prevention in Schizophrenia and Related Disorders: A Systematic Review.

Catalog

Books, media, physical & digital resources